MCHM Macrochem (MM)

MacroChem CEO to Address Sachs-Bloomberg Forum for Healthcare Investing & Partnering LEXINGTON, Mass., March 31 /PRNewswire-FirstCall/ -- MacroChem Corporation announced today that its president and CEO, Robert J. DeLuccia, willaddress healthcare analysts and portfolio managers attending The Sachs- Bloomberg L.P. 3rd Annual Global Biotech Forum for Investing & Partnering, opening tomorrow at the Fairmont Copley Plaza in Boston, MA. The Sachs-Bloomberg forum offers a platformfor healthcare companies to meet with more than 400 leading investors and pharmaceutical company executives. In addition to corporate presentations, the program includes in- depth panel discussions on partnering and investing in life sciences companies, led by international executives from leading investors, pharmaceutical and biotech companies. For in-depth information about the event, visit http://www.sachsforum.com/global4_fs.html MacroChem is a specialty pharmaceutical company that innovates, develops and commercializes pharmaceuticals administered in novel ways, to treat important medical conditions. MacroChem is developing three products containing its patented drug-absorption enhancer, SEPA(R): Topiglan(R), a SEPA-enhanced alprostadil for topical treatment of erectile dysfunction; Opterone(TM), a SEPA-enhanced topical treatment for men with testosterone deficiency; and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis. For further information please consult http://www.macrochem.com/ With the exception of historical information contained in this press release, the matters described herein are forward-looking statements and are subject to various riskfactors that could cause actual results to differ materially from those expressed in the forward-looking statements. The relevant risk factors are set forth in MacroChem's annual report on Form 10-K as filed with the SEC and include, without limitation, risks regarding product development, clinical trials, dependence on third parties for development and licensing arrangements, and risks involving regulatory approval of products, and patents and licenses. Visit our web site at: http://www.macrochem.com/ Contact: Bernard Patriacca - VP/CFO (781) 862-4003 Media Contact: James Chiafery (LaVoie Group) (781) 599-4774 DATASOURCE: MacroChem Corporation CONTACT: Bernard Patriacca - VP/CFO of MacroChem, +1-781-862-4003; or Media Contact, James Chiafery of LaVoie Group, +1-781-599-4774 Web site: http://www.macrochem.com/

Copyright